Ramesh OMRANIPOUR, Anahita BORJIAN, Mohammad Amin BORJIAN, Newsha NAZARIAN

Oncofertility and Fertility Preservation Counseling in Iranian Women with Breast Cancer

OBJECTIVE To introduce the importance of oncofertility and fertility preservation counseling in women with breast cancer and to discuss possible impacting factors regarding Iranian breast cancer female patients’ participation in fertility preservation programs. METHODS In this study, 146 females with breast cancer were studied. The eligibility criteria were: female patients with breast cancer, to be in their reproductive age (between 14 to 45 years). Patients with at least one of the following criteria were excluded from this study: Having received chemo-radiotherapy before the current treatment, having received hormonal or pharmacological assisted reproductive treatments previously and unwillingness to participate in this study. RESULTS Out of 146 patients, oncofertility counseling was requested for 55 eligible patients. Oocyte-egg cryopreservation was successful in 16 patients (29.10%). In four patients (7.27%), the number of ovarian follicles was inadequate. For 10 patients (18.18%), oncologists advised initiation of chemotherapy before completion of preservation programs, and 25 patients (45.45%) decided not to continue their preservation programs. Out of 91 patients not receiving oncofertility counseling, 76 patients (83.50%) declared that their family planning was completed, 11 patients (12.10%) were in the early stages of breast cancer and did not require chemoradiotherapy, and four patients (4.40%) were in metastatic stages. We also found that contrary to the number of living children of patients, neither age nor marital status has an impact on their decisions to participate in fertility preservation programs. CONCLUSION To improve the quality of lives of Iranian women suffering from breast cancer, it is of utmost importance to raise awareness of oncofertility and to investigate the reasons for the under-implementation of fertility preservation programs in cancer patients.

PDF

___

1. Salama M, Ataman L, Taha T, Azmy O, Braham M, Douik F, et al. Building Oncofertility Core Competency in Developing Countries: Experience From Egypt, Tunisia, Brazil, Peru, and Panama. J Glob Oncol 2018;4:1–11.
2. Vesali S, Navid B, Mohammadi M, Karimi E, OmaniSamani R. Little information about fertility preservation is provided for cancer patients: A survey of oncologists’ knowledge, attitude and current practice. Eur J Cancer Care (Engl) 2019;28(1):e12947.
3. Anazodo A, Laws P, Logan S, Saunders C, Travaglia J, Gerstl B, et al. How can we improve oncofertility care for patients? A systematic scoping review of current international practice and models of care. Hum Reprod Update 2019;25(2):159–79.
4. Logan S, Perz J, Ussher JM, Peate M, Anazodo A1. A systematic review of patient oncofertility support needs in reproductive cancer patients aged 14 to 45 years of age. Psychooncology 2018;27(2):401–9.
5. Hovatta O. Cryopreservation of testicular tissue in young cancer patients. Hum Reprod Update 2001;7(4):378–83.
6. Reebals JF, Brown R, Buckner EB. Nurse practice issues regarding sperm banking in adolescent male cancer patients. J Pediatr Oncol Nurs 2006;23(4):182–8.
7. Quinn GP, Vadaparampil ST, Gwede CK, Miree C, King LM, Clayton HB, et al. Discussion of fertility preservation with newly diagnosed patients: oncologists’ views. J Cancer Surviv 2007;1(2):146–55.
8. Rashedi AS, de Roo SF, Ataman LM, Edmonds ME, Silva AA, Scarella A, et al. Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe. J Glob Oncol 2018;4:1–16.
9. Petersen LF, Moravek M, Woodruff TK, Jeruss JS. Oncofertility Options for Young Women With Breast Cancer. The Breast. Elsevier Inc; 2018. p. 773–7. 10. Mousavi SM, Montazeri A, Mohagheghi MA, Jarrahi AM, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. Breast J 2007;13(4):38391.
11. Kim H, Kim SK, Lee JR, Hwang KJ, Suh CS Kim SH. Fertility preservation for patients with breast cancer: T he Korean Society for Fertility Preservation clinical guidelines. Clin Exp Reprod Med 2017;44(4):181–6.
12. Lambertini M, Fontana V, Massarotti C, Poggio F, Dellepiane C, Iacono G, et al. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study. Breast 2018;41:51–6.
13. Salama M, Ataman-Millhouse L, Sobral F, Terrado G, Scarella A, Bourlon MT, et al. Barriers and Opportunities of Oncofertility Practice in Nine Developing Countries and the Emerging Oncofertility Professional Engagement Network. J Glob Oncol 2018;4:1–7.
14. Dolatkhah R, Somi MH, Kermani IA, Ghojazadeh M, Jafarabadi MA, Farassati F, et al. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC Public Health 2015;15:997.
15. Nafissi N, Khayamzadeh M, Zeinali Z, Pazooki D, Hosseini M, Akbari ME. Epidemiology and Histopathology of Breast Cancer in Iran versus Other Middle Eastern Countries %J Middle East Journal of Cancer 2018;9(3):243–51.
16. Tazhibi M, Dehkordi ZF, Babazadeh S. Trends in breast cancer incidence rates by age and tumor characteristics of women in the city of Isfahan for the period 2001-2010: An application of joinpoint analysis. J Res Med Sci 2014;19(4):319–25.
17. Geue K, Richter D, Schmidt R, Sender A, Siedentopf F, Brähler E, et al. The desire for children and fertility issues among young German cancer survivors. J Adolesc Health 2014;54(5):527–35.
18. Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010;28(31):4683–6.
19. Letourneau JM, Sinha N, Wald K, Harris E, Quinn M, Imbar T, et al. Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer. Hum Reprod 2017;32(10):2123–9.
20. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, et al. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat 2017;165(1):151–9.
21. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008;26(16):2630–5.
22. Yee S, Fuller-Thomson E, Lau A, Greenblatt EM. Fertility preservation practices among Ontario oncologists. J Cancer Educ 2012;27(2):362–8.
23. Goodman LR, Balthazar U, Kim J, Mersereau JE. Trends of socioeconomic disparities in referral patterns for fertility preservation consultation. Hum Reprod 2012;27(7):2076–81.